Clear Street has initiated coverage on Dianthus Therapeutics Inc (DNTH) with a Buy rating, effective September 16, 2025. This marks the firm's first assessment of the biotechnology company, which focuses on developing complement therapeutics for severe autoimmune and inflammatory diseases.
Dianthus Therapeutics, headquartered in New York City, is a clinical-stage biotechnology firm employing 78 full-time staff. The company went public on June 21, 2018. Its leading product candidate, DNTH103, is designed to selectively bind to the active form of C1s and is engineered for convenient self-administration via subcutaneous injection.
Dianthus has a market capitalization of $1.5 billion and reported a trailing twelve-month EPS of -3.25. Upcoming earnings are projected for August 5, 2026, with an EPS estimate of -0.93 and revenue expected at $219,810.
The analyst consensus as of November 1, 2025, shows 9 Strong Buy, 10 Buy, and 1 Hold ratings, reflecting a general positive outlook on the stock. Analyst ratings can shift as new information becomes available, highlighting the importance of considering multiple factors in investment decisions.
This update provides insight into the growing interest in Dianthus Therapeutics as it advances its clinical trials for DNTH103 in generalized Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy.